Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04003636




Registration number
NCT04003636
Ethics application status
Date submitted
28/06/2019
Date registered
1/07/2019
Date last updated
5/03/2024

Titles & IDs
Public title
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Scientific title
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma
Secondary ID [1] 0 0
MK-3475-966
Secondary ID [2] 0 0
3475-966
Universal Trial Number (UTN)
Trial acronym
KEYNOTE-966
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Biliary Tract Carcinoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Pembrolizumab
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Cisplatin
Treatment: Drugs - Placebo

Experimental: Arm A (Pembrolizumab+Gemcitabine+Cisplatin) - Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.

Placebo Comparator: Arm B (Placebo+Gemcitabine+Cisplatin) - Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.


Other interventions: Pembrolizumab
Pembrolizumab by intravenous (IV) infusion

Treatment: Drugs: Gemcitabine
Gemcitabine by IV infusion

Treatment: Drugs: Cisplatin
Cisplatin by IV infusion

Treatment: Drugs: Placebo
Placebo to pembrolizumab
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 38 months
Secondary outcome [1] 0 0
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)
Timepoint [1] 0 0
Up to approximately 26 months
Secondary outcome [2] 0 0
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Timepoint [2] 0 0
Up to approximately 26 months
Secondary outcome [3] 0 0
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
Timepoint [3] 0 0
Up to approximately 38 months
Secondary outcome [4] 0 0
Number of Participants Who Experience One or More Adverse Events (AE)
Timepoint [4] 0 0
Up to approximately 38 months
Secondary outcome [5] 0 0
Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)
Timepoint [5] 0 0
Up to approximately 38 months

Eligibility
Key inclusion criteria
Inclusion Criteria

- Has histologically confirmed diagnosis of advanced (metastatic) and/or unresectable
(locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or
gallbladder cancer)

- Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST
1.1), as determined by the site investigator

- Participants with a history of hepatitis B or hepatitis C can be enrolled if they meet
study criteria

- Is able to provide archival tumor tissue sample or newly obtained core or excisional
biopsy of a tumor lesion

- Has a life expectancy of greater than 3 months

- Has adequate organ function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Has had previous systemic therapy for advanced (metastatic) or unresectable (locally
advanced) biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or
gallbladder cancer)

- Has ampullary cancer

- Has small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology
and/or mucinous cystic neoplasms

- Has received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-
programmed cell death ligand 1 or 2 (anti-PD-L1, anti-PD-L2) agent or with an agent
directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic
T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)

- Has a known history of, or any evidence of, central nervous system (CNS) metastases
and/or carcinomatous meningitis, as assessed by local site investigator

- Has had an allogenic tissue/solid organ transplant

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/09/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
29/11/2024
Actual
Sample size
Target
Accrual to date
Final
1069
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Liverpool Hospital ( Site 0707) - Liverpool
Recruitment hospital [2] 0 0
Mid North Coast Cancer Institute ( Site 0708) - Port Macquarie
Recruitment hospital [3] 0 0
Gallipoli Medical Research Foundation ( Site 0705) - Brisbane
Recruitment hospital [4] 0 0
Eastern Health ( Site 0704) - Box Hill
Recruitment hospital [5] 0 0
Western Health-Sunshine Hospital ( Site 0709) - St Albans
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [3] 0 0
4120 - Brisbane
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3021 - St Albans
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Oklahoma
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
South Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Virginia
Country [12] 0 0
Argentina
State/province [12] 0 0
Caba
Country [13] 0 0
Argentina
State/province [13] 0 0
Tucuman
Country [14] 0 0
Argentina
State/province [14] 0 0
La Rioja
Country [15] 0 0
Belgium
State/province [15] 0 0
Antwerpen
Country [16] 0 0
Belgium
State/province [16] 0 0
Bruxelles-Capitale, Region De
Country [17] 0 0
Belgium
State/province [17] 0 0
Hainaut
Country [18] 0 0
Belgium
State/province [18] 0 0
Liege
Country [19] 0 0
Belgium
State/province [19] 0 0
Oost-Vlaanderen
Country [20] 0 0
Belgium
State/province [20] 0 0
Vlaams-Brabant
Country [21] 0 0
Brazil
State/province [21] 0 0
Minas Gerais
Country [22] 0 0
Brazil
State/province [22] 0 0
Rio Grande Do Sul
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio de Janeiro
Country [24] 0 0
Brazil
State/province [24] 0 0
Sao Paulo
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Chile
State/province [28] 0 0
Araucania
Country [29] 0 0
Chile
State/province [29] 0 0
Coquimbo
Country [30] 0 0
Chile
State/province [30] 0 0
Lbtdr Gen Bernardo O Higgins
Country [31] 0 0
Chile
State/province [31] 0 0
Region M. De Santiago
Country [32] 0 0
China
State/province [32] 0 0
Anhui
Country [33] 0 0
China
State/province [33] 0 0
Beijing
Country [34] 0 0
China
State/province [34] 0 0
Chongqing
Country [35] 0 0
China
State/province [35] 0 0
Fujian
Country [36] 0 0
China
State/province [36] 0 0
Guangdong
Country [37] 0 0
China
State/province [37] 0 0
Hainan
Country [38] 0 0
China
State/province [38] 0 0
Heilongjiang
Country [39] 0 0
China
State/province [39] 0 0
Hunan
Country [40] 0 0
China
State/province [40] 0 0
Jiangsu
Country [41] 0 0
China
State/province [41] 0 0
Jilin
Country [42] 0 0
China
State/province [42] 0 0
Shanghai
Country [43] 0 0
China
State/province [43] 0 0
Shanxi
Country [44] 0 0
China
State/province [44] 0 0
Sichuan
Country [45] 0 0
China
State/province [45] 0 0
Tianjin
Country [46] 0 0
China
State/province [46] 0 0
Zhejiang
Country [47] 0 0
France
State/province [47] 0 0
Gironde
Country [48] 0 0
France
State/province [48] 0 0
Hauts-de-Seine
Country [49] 0 0
France
State/province [49] 0 0
Herault
Country [50] 0 0
France
State/province [50] 0 0
Ille-et-Vilaine
Country [51] 0 0
France
State/province [51] 0 0
Puy-de-Dome
Country [52] 0 0
France
State/province [52] 0 0
Val-de-Marne
Country [53] 0 0
Germany
State/province [53] 0 0
Baden-Wurttemberg
Country [54] 0 0
Germany
State/province [54] 0 0
Bayern
Country [55] 0 0
Germany
State/province [55] 0 0
Hessen
Country [56] 0 0
Germany
State/province [56] 0 0
Niedersachsen
Country [57] 0 0
Germany
State/province [57] 0 0
Nordrhein-Westfalen
Country [58] 0 0
Germany
State/province [58] 0 0
Sachsen-Anhalt
Country [59] 0 0
Germany
State/province [59] 0 0
Sachsen
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Hamburg
Country [62] 0 0
Hong Kong
State/province [62] 0 0
Hong Kong
Country [63] 0 0
Hong Kong
State/province [63] 0 0
Kowloon
Country [64] 0 0
Ireland
State/province [64] 0 0
Cork
Country [65] 0 0
Ireland
State/province [65] 0 0
Dublin
Country [66] 0 0
Israel
State/province [66] 0 0
Haifa
Country [67] 0 0
Israel
State/province [67] 0 0
Jerusalem
Country [68] 0 0
Israel
State/province [68] 0 0
Petah Tikva
Country [69] 0 0
Israel
State/province [69] 0 0
Tel Aviv
Country [70] 0 0
Italy
State/province [70] 0 0
Abruzzo
Country [71] 0 0
Italy
State/province [71] 0 0
Bologna
Country [72] 0 0
Italy
State/province [72] 0 0
Catania
Country [73] 0 0
Italy
State/province [73] 0 0
Milano
Country [74] 0 0
Italy
State/province [74] 0 0
Pisa
Country [75] 0 0
Italy
State/province [75] 0 0
Roma
Country [76] 0 0
Italy
State/province [76] 0 0
Verona
Country [77] 0 0
Japan
State/province [77] 0 0
Aichi
Country [78] 0 0
Japan
State/province [78] 0 0
Chiba
Country [79] 0 0
Japan
State/province [79] 0 0
Hyogo
Country [80] 0 0
Japan
State/province [80] 0 0
Kagawa
Country [81] 0 0
Japan
State/province [81] 0 0
Kanagawa
Country [82] 0 0
Japan
State/province [82] 0 0
Osaka
Country [83] 0 0
Japan
State/province [83] 0 0
Tokyo
Country [84] 0 0
Japan
State/province [84] 0 0
Fukuoka
Country [85] 0 0
Japan
State/province [85] 0 0
Kyoto
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Jeonranamdo
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Kyonggi-do
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Taegu-Kwangyokshi
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Taejon-Kwangyokshi
Country [90] 0 0
Korea, Republic of
State/province [90] 0 0
Seoul
Country [91] 0 0
Malaysia
State/province [91] 0 0
Johor
Country [92] 0 0
Malaysia
State/province [92] 0 0
Kuala Lumpur
Country [93] 0 0
Malaysia
State/province [93] 0 0
Pulau Pinang
Country [94] 0 0
Malaysia
State/province [94] 0 0
Wilayah Persekutuan Putrajaya
Country [95] 0 0
Netherlands
State/province [95] 0 0
Limburg
Country [96] 0 0
Netherlands
State/province [96] 0 0
Noord-Holland
Country [97] 0 0
Netherlands
State/province [97] 0 0
Zuid-Holland
Country [98] 0 0
Netherlands
State/province [98] 0 0
Groningen
Country [99] 0 0
Netherlands
State/province [99] 0 0
Utrecht
Country [100] 0 0
New Zealand
State/province [100] 0 0
Auckland
Country [101] 0 0
Spain
State/province [101] 0 0
Asturias
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Madrid
Country [104] 0 0
Spain
State/province [104] 0 0
Malaga
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taipei
Country [106] 0 0
Taiwan
State/province [106] 0 0
Kaohsiung
Country [107] 0 0
Taiwan
State/province [107] 0 0
Taichung
Country [108] 0 0
Taiwan
State/province [108] 0 0
Tainan
Country [109] 0 0
Taiwan
State/province [109] 0 0
Taoyuan
Country [110] 0 0
Thailand
State/province [110] 0 0
Krung Thep Maha Nakhon
Country [111] 0 0
Thailand
State/province [111] 0 0
Ubon Ratchathani
Country [112] 0 0
Thailand
State/province [112] 0 0
Chiang Mai
Country [113] 0 0
Thailand
State/province [113] 0 0
Khon Kaen
Country [114] 0 0
Thailand
State/province [114] 0 0
Udon Thani
Country [115] 0 0
Turkey
State/province [115] 0 0
Adana
Country [116] 0 0
Turkey
State/province [116] 0 0
Ankara
Country [117] 0 0
Turkey
State/province [117] 0 0
Istanbul
Country [118] 0 0
Turkey
State/province [118] 0 0
Izmir
Country [119] 0 0
Turkey
State/province [119] 0 0
Kayseri
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Aberdeen City
Country [121] 0 0
United Kingdom
State/province [121] 0 0
London, City Of
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Surrey
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Belfast
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Coventry
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus
gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable
biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin
is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04003636
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/ct2/show/NCT04003636